Claims for Patent: 8,293,240

Summary for Patent: 8,293,240

Title:	Method of treating drug-resistant cancer
Abstract:	Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and/or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and/or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.
Inventor(s):	Newell; Martha Karen (Colorado Springs, CO), Newell; Evan (Menlo Park, CA), Villalobos-Menuey; Elizabeth (Monument, CO)
Assignee:	The Regents of the University of Colorado (Denver, CO)
Application Number:	12/390,753
Patent Claims:	1. A method, comprising: administering; to a subject having a drug-resistant cancer, a therapeutically acceptable amount of a composition of a fatty acid metabolism inhibitor and a pharmaceutically acceptable carrier wherein the subject is not otherwise indicated for treatment with the compound and further comprising administering a glucose metabolism inhibitor and optionally one or more of the chemotherapeutic agents selected from the group consisting of methotrexate, trimetrexate, adriamycin, taxotere, doxorubicin, 5-flurouracil, vincristine, vinblastine, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol, tamoxifen, paclitaxet, docetaxel, capecitabine, and goserelin acetate, wherein the subject is not administered another anti-cancer agent for treating the cancer other than the fatty acid metabolism inhibitor, the glucose metabolism inhibitor and the chemotherapeutic, and wherein the composition is formulated in a colloidal dispersion system that is a liposome. 2. The method of claim 1 wherein the fatty acid metabolism inhibitor comprises at least one of etomoxir, oxfenicine, methyl palmoxirate, metoprolol, amiodarone, perhexiline, aminocarnitine, hydrazonopropionic acid, 4-bromocrotonic acid, trimetazidine, hypoglycin, dichloroacetate, methylene cyclopropyl acetic acid, or beta-hydroxy butyrate. 3. The method of claim 1 in which the fatty acid metabolism inhibitor is an oxirane carboxylic acid compound capable of inhibiting fatty acid metabolism, or a pharmacologically acceptable salt thereof, wherein the subject is not otherwise indicated for treatment with the compound, and the oxirane carboxyclic acid compound or pharmaceutically acceptable salt thereof is not ranolazine. 4. The method of claim 3 wherein the oxirane carboxylic acid compound has the formula: ##STR00013## wherein R.sub.1 represents a hydrogen atom, a halogen atom, a 1-4C alkyl group, a 1-4C alkoxy group, a nitro group or a trifluoromethyl group, R2 has one of the meanings of R1, R3 represents a hydrogen atom or a 1-4C alkyl group, Y represents the grouping --O--(CH2)m--, m is 0 or a whole number from 1 to 4, and n is a whole number from 2 to 8 wherein the sum of m and n is a whole number from 2 to 8 wherein the sum of m and n is a whole number from 2 to 8; and wherein the oxirane carboxyclic acid compound is not ranolazine. 5. The method of claim 4 wherein the oxirane carboxylic acid compound is etomoxir. 6. The method of claim 1 wherein the glucose metabolism inhibitor is a 2-deoxyglucose compound. 7. The method of claim 6 wherein the 2-deoxyglucose compound has the formula: ##STR00014## wherein X represents an O or S atom; R1 represents a hydrogen atom or a halogen atom; R2 represents a hydroxyl group, a halogen atom, a thiol group, or CO--R6; R3, R4, and R5 each represent a hydroxyl group, a halogen atom, or CO--R6, R6 represents an alkyl group of from 1 to 20 carbon atoms, and at least two of R3, R4, and R5 are hydroxyl groups. 8. The method of claim 7 wherein the 2-deoxyglucose compound is 2-deoxy-D-glucose. 9. The method of claim 1 wherein the subject is not indicated for treatment of cardiac insufficiency. 10. The method of claim 1 wherein cells comprising the cancer derive a majority of their metabolic energy through fatty acid metabolism. 11. The method of claim 1 wherein the chemotherapeutic agents is docetaxel. 12. The method of claim 1 wherein the fatty acid metabolism inhibitor is dichloroacetate and the glucose metabolism inhibitor is 2-deoxy-D-glucose or the pharmaceutically acceptable salts thereof.

Details for Patent 8,293,240

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-01-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-01-08
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2024-01-08